Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 1843

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 7
Chunk 1843
---
 $1.2 billion in 2018, a compound annual growth rate of 75%. Before Horizon,
he spent more than 11 years as Managing Director and Head of the Life Sciences Investment Banking Group at JMP Securities. Mr. Carey was
also Managing Director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. He received his B.B.A. in Accounting
from the University of Notre Dame. Mr. Carey currently serves on the Board of Beyond Cancer Ltd. and Sangamo Therapeutics, Inc.

Our Board of Directors
believes that Mr. Carey’s experience and perspective advising the Company and other life sciences companies in connections with
financings and strategic transactions, as well as his depth of operating and senior management experience in our industry, provide him
with the qualifications and skills to serve as a director.

Robert
Scott Goodman, Director

Robert
Scott Goodman joined our Board of Directors in June 2025. Mr. Goodman brings more than 30 years of executive commercial leadership experience
and success spanning venture-backed emerging businesses to Fortune 50 companies. Most recently, he served on the Board of Directors of
Fourth Frontier, a pioneering health tech company, where he contributed to the company’s 510k FDA device approval and supported
a successful Series B financing. Mr. Goodman served as the Chief Commercial Officer for pharmaceutical company WEP Clinical from 2023-2024,
where he helped accelerate and increase total contract values and revenue growth by over 30% YOY. Mr. Goodman served as Division President
at BioTelemetry, where he led a $2.1B sell-side transaction to Royal Philips in 2021. Mr. Goodman also has extensive executive sales
experience, serving as SVP, Sales & Marketing of Cardiocore (later acquired by BioTelemetry) from 2008-2017 and as Thermo Fisher’s
Senior Director, Head of Sales & Marketing from 2007-2008.

Our
Board of Directors believes that Mr. Goodman’s strategic insight and commercial acumen have consistently delivered value across the healthcare
and life sciences sectors, and provide him with the qualifications and skills to serve as a director.

86

Term of Office of Directors

Our directors are elected at each
annual meeting of stockholders and serve until their successors are elected and qualified at the next annual meeting of stockholders,
or until their prior death, resignation or removal.

Family Relationships

There are no family relationships
among any of our current or former directors or